Penn Dermatology Faculty and Investigators
John R. Stanley, M.D.
Professor of Dermatology
Department: Dermatology
Contact information
University of Pennsylvania School of Medicine
Department of Dermatology
415 Curie Boulevard, 211 Clinical Research Building
Philadelphia, PA 19104
Department of Dermatology
415 Curie Boulevard, 211 Clinical Research Building
Philadelphia, PA 19104
Office: 215-898-3240
Fax: 215-573-2033
Fax: 215-573-2033
Education:
B.A. (Physics)
Cornell University, 1970.
M.D.
Harvard Medical School, 1974.
B.A. (Physics)
Cornell University, 1970.
M.D.
Harvard Medical School, 1974.
Post-Graduate Training
Internship in Medicine, University of Washington Affiliated Hospitals, Washington, DC, 1974-1975.
Resident in Dermatology, New York University Medical Center, New York, NY, 1975-1977.
Chief Resident in Dermatology, New York University Medical Center, New York, NY, 1977-1978.
Internship in Medicine, University of Washington Affiliated Hospitals, Washington, DC, 1974-1975.
Resident in Dermatology, New York University Medical Center, New York, NY, 1975-1977.
Chief Resident in Dermatology, New York University Medical Center, New York, NY, 1977-1978.
Certifications
American Board of Dermatology, 1978.
Special Certification in Immunodermatology from the American Board of Dermatology, 1985.
Permanent linkAmerican Board of Dermatology, 1978.
Special Certification in Immunodermatology from the American Board of Dermatology, 1985.
Selected Publications
Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, Makni S, Turki H, Hachiya T, Kuroda K, Stanley JR, Masmoudi H, Amagai M: Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus. J Dermatol Sci 70(1): 19-25. doi: 10.1016/j.jdermsci.2013.02.002. April 2013 Notes: Epub 2013 Feb 19.Kouno K, Lin C, Schechter N, Siegel D, Yang X, Seykora JT, Stanley JR: Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody. J Invest Dermatol. Advance online publication 4 April 2013; doi: 10.1038/jid.2013.85 Page: doi: 10.1038/jid.2013.85. February 2013 Notes: Epub ahead of print.
Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS: Adjuvant rituximab therapy of pemphigus: A single center experience with 31 patients. Arch Dermatol 148: 1031-1036, 2012.
Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR: Homologous regions of heavy chain complementarity determining region 3 (H-CDR#) of pemphigus antibodies cause pathogenicity. J Clin Invest 120: 4111-4117, 2010.
Yamagami J, Kacir S, Ishii K, Payne AS, Siegel DL, Stanley JR: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol 183(9): 5615-5621. doi: 10.4049/jimmunol.0901691. November 2009.
Stanley JR, Ishii K, Siegel DL, Payne AS: Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy. Veterinary Dermatology 20: 327-330, 2009.
Yokouchi M, Saleh MA, Kuroda K, Hachiya T, Stanley JR, Amagai M, Ishii K: Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J Invest Dermatol 129: 2156-2166, 2009.
Yamagami J, Kacir S, Ishii K, Payne AS, Siegel DL, Stanley JR: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol 183: 5615-5621, 2009.
Stanley JR, Amagai M: Autoimmune bullous diseases: historical perspectives. J Invest Dermatol. (electronic publication on Nature Publishing JID website) (eds.). 128: E16-E18, 2008.
Ishii K, Lin C, Siegel DL, Stanley JR: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 128: 939-948, 2008.